Athira Pharma Q3 net loss $15.7M; ACT-AD trial enrollment completed

LeonaBio, Inc.

2022-Q3 EPS reported -$1.05

Net loss of $15.7M ($0.42 per share) vs $8.5M loss in Q3 2020; R&D spend $10.7M.
Cash, cash equivalents and investments $339.4M as of Sept 30, 2021, up from $268.2M at Dec 31, 2020.
Completed enrollment in Phase 2 ACT-AD trial (77 subjects); topline data expected H1 2022.
LIFT-AD Phase 2/3 actively recruiting; topline data expected by end of 2022.
SHAPE Phase 2 trial (Parkinson's dementia) anticipated to initiate by end of 2021; IND for ATH-1020 expected by end of 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.